Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listEtoricoxib

Etoricoxib

Synonym(s):5-Chloro-3-[4-(methylsulfonyl)phenyl]-2-(2-methyl-5-pyridinyl)pyridine;5-Chloro-6′-methyl-3-[4-(methylsulfonyl)phenyl]-2,3′-bipyridine

  • CAS NO.:202409-33-4
  • Empirical Formula: C18H15ClN2O2S
  • Molecular Weight: 358.84
  • MDL number: MFCD06797512
  • EINECS: 682-421-5
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-17 08:48:38
Etoricoxib Structural

What is Etoricoxib?

Absorption

Bioavailability is 100% following oral administration.

Toxicity

This reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet). Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo

Description

Etoricoxib is a COX-2 inhibitor developed as a follow-up of rofecoxib for treating osteoarthritis, rheumatoid arthritis, dysmenorrhoea, gout, ankylosing spondylitis and pain. Several processes describe the preparation of etoricoxib in 4 or 5 steps from 6- methyl nicotinate. The critical step is the novel pyridine construction using the annulation of a ketosutfone with a vinamidinium synthon. In human whole blood, in vitro, the IC50 value obtained for inhibition of COX-2 is 1.1 μM compared to 116 μM obtained for inhibition of COX-1. Thus, etoricoxib is the most selective COX-2 inhibitor to date, with a COX-IKOX- 2 ratio of IC50 values of 106 for etoricoxib as compared to 35, 30, 7.6 for rofecoxib, valdecoxib and celecoxib, respectively. Its in vivo potency is generally comparable to that of rofecoxib in animal models against inflammation (carrageenan-induced paw edema), pyrexia (LPS-induced pyresis), pain (carrageenan-induced hyperalgesia) and arthritis (adjuvant-induced arthritis).

Chemical properties

Off-White Powder

Originator

Merck & Co (USA)

The Uses of Etoricoxib

A specific inhibitor of COX-2 .

The Uses of Etoricoxib

anti-inflammatory, analgesic;cyclooxygenase inhibitor

The Uses of Etoricoxib

For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.

The Uses of Etoricoxib

Etoricoxib is a dipyridinyl compound that demonstrates high in vitro and ex vivo selectivity for COX-2 over COX-1 in several assays, e.g., in the production of PGE2 by CHO cells expressing either COX-2 (IC50 = 79 nM) or COX-1 (IC50 > 50 μM). Oral etoricoxib is well absorbed and metabolized extensively via oxidation, with metabolites excreted largely in the urine.[Cayman Chemical]

The Uses of Etoricoxib

The active substance etoricoxib belongs to a group of medicines called selective COX-2 inhibitors. These belong to a family of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). Etoricoxib helps to reduce the pain and swelling (inflammation) in the joints and muscles of people 16 years of age and older with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and gout. It is also used for the short-term treatment of moderate pain after dental surgery in people 16 and older. Labeled Etoricoxib, intended for use as an internal standard for quantifying Etoricoxib by GC- or LC-mass spectrometry.

Background

Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.

What are the applications of Application

Etoricoxib is a specific inhibitor of COX-2

Indications

For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.

Definition

ChEBI: A member of the class of bipyridines that is 2,3'-bipyridine which is substituted at the 3, 5, and 6' positions by 4-(methylsulfonyl)phenyl, chlorine, and methyl groups, respectively.

brand name

Arcoxia

Pharmacokinetics

Etoricoxib is rapidly absorbed, with an oral bioavailability of 80 to 100%, and reaches maximum plasma concentrations in 1 to 2 hours after dosing. Food decreases the rate of absorption but has no effect on the extent of absorption. It exhibits a long elimination half-life of approximately 22 hours, demonstrating linear plasma pharmacokinetics with no accumulation during multiple dosing.

Pharmacokinetics

Etoricoxib is well tolerated with dose-proportional pharmacokinetics. It does not affect on bleeding time or platelet ag regation. The gastrointestinal tolerability of etoricoxib is excellent, as demonstrated by [51Cr] excretion models in rats and squirrel monkeys. Moreover, etoricoxib, unlike naproxen, is not associated with significant inhibition of gastric mucosal PGE2 synthesis compared to placebo. Etoricoxib is highly absorbed, with a tmax of 1.5 h and a half-life of approximately 15-22h. Five metabolites, weak inhibitors of COX-1 and COX-2, have been identified after renal excretion. Finally, although multiple CYP enzymes are involved in the metabolism of etoricoxib (CYP3A4 being the major contributor), etoricoxib is not a potent CYP3A4 inhibitor or inducer. In patients undergoing molar extraction, etoricoxib showed similar efficacy to naproxen sodium with a longer duration of analgesia than acetaminophen/codeine (approximately >24 h, 22 h and 5.2 h, respectively) and a better total pain relief score over 8 h. Similar efficacy of etoricoxib and naproxen was also seen in patients suffering from osteoarthritis. In treating rheumatoid arthritis and ankylosing spondylitis, etoricoxib demonstrated significantly superior efficacy to naproxen and placebo. Etoricoxib did not affect the pharmacokinetics of prednisolone (i.v. or p.0.), and its co-administration with antacids showed insignificant effects on maximal concentration and absorption.

Clinical Use

Etoricoxib is a selective COX-2 inhibitor being developed for postsurgical treatment of dental pain (120 mg) and osteoarthritis. It has a methylsulfonyl group common to the other coxib inhibitors.

Synthesis

The synthesis of etoricoxib (8) was explored extensively by the Merck process research group. Key intermediate 85 was synthesized through at least three different routes. In the Horner-Wittig approach, 6-methyl methylnicotinate (79) was converted into Weinreb amide 80 in 95% yield. Amide 80 was then converted to aldehyde 81 via a DIBAL-H mediated reduction. Subsequent treatment of a solution of aldehyde 81 in isopropyl acetate with aniline and diphenyl phosphite provided N,P-acetal 82 in 87% yield. The Horner-Wittig reaction of N,P-acetal 82 with 4-methanesulfonylbenzaldehyde (83) furnished enamine 84, which was hydrolyzed to ketosulfone 85. A Grignard approach was also developed in the preparation of ketosulfone 85. Addition of Grignard reagent 86 to Weinreb amide 80 in toluene/THF provided ketosulfide 85 in 80% yield. Tungstate-catalyzed oxidation of ketosulfide 87 using hydrogen peroxide provided ketosulfone 85 in 89% yield by simple filtration. Ketosulfone 85 was prepared through Claisen condensation protocol as well. Thus, reaction of 4-methanesulfonyl phenyl acetic acid (88) with methyl nicotinate 79 under Ivanoff condition, i.e., the magnesium dianion in THF, resulted 58% yield of ketosulfone 85. Treatment of ketosulfone 85 with a three-carbon electrophile, 2-chloro-N,Ndimethylaminotrimethinium hexafluorophos-phate (89) in the presence of potassium t-butoxide at ambient temperature resulted adduct 90. Inverse quench of adduct 90 into a mixture of HOAc /TFA led to the putative intermediate 91. Ring closure of the pyridine ring occurred upon heating at reflux in the presence of an excess of aqueous ammonium hydroxide to give desired etoricoxib (8) in 97% yield in a one-pot process from 85.

Synthesis_202409-33-4

Drug interactions

Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac, increased risk of side effects and haemorrhage.
Antibacterials: possibly increased risk of convulsions with quinolones; concentration reduced by rifampicin.
Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparin, dabigatran and edoxaban - avoid long term use with edoxaban.
Antidepressants: increased risk of bleeding with SSRIs and venlaflaxine.
Antidiabetic agents: effects of sulphonylureas enhanced.
Antiepileptics: possibly increased phenytoin concentration.
Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
Ciclosporin: may potentiate nephrotoxicity
Cytotoxics: reduced excretion of methotrexate; possibly reduced excretion of pemetrexed; increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity.

Metabolism

Etoricoxib is metabolized involving oxidation of its 6′-methyl group primarily by CYP3A4 but is not an inhibitor of CYP3A4. Other metabolites include 1′-N-oxide and glucuronides. Etoricoxib is primarily excreted as metabolites into the urine.

Metabolism

Hepatic, primarily via CYP3A4.

Properties of Etoricoxib

Melting point: 134-135°C
Boiling point: 510.0±50.0 °C(Predicted)
Density  1.298±0.06 g/cm3(Predicted)
storage temp.  Inert atmosphere,2-8°C
solubility  DMSO : 100 mg/mL (278.68 mM; Need ultrasonic)
pka 4.5(at 25℃)
form  neat
form  Solid
color  Light yellow to yellow
BRN  8073797
CAS DataBase Reference 202409-33-4(CAS DataBase Reference)

Safety information for Etoricoxib

Signal word Danger
Pictogram(s)
ghs
Skull and Crossbones
Acute Toxicity
GHS06
GHS Hazard Statements H302:Acute toxicity,oral
H310:Acute toxicity,dermal
Precautionary Statement Codes P262:Do not get in eyes, on skin, or on clothing.
P264:Wash hands thoroughly after handling.
P264:Wash skin thouroughly after handling.
P270:Do not eat, drink or smoke when using this product.
P280:Wear protective gloves/protective clothing/eye protection/face protection.
P301+P312:IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

Computed Descriptors for Etoricoxib

InChIKey MNJVRJDLRVPLFE-UHFFFAOYSA-N

Abamectin manufacturer

Gonane Pharma

1Y
Phone:+919819380043
Whatsapp: +91 9819380043
product: Etoricoxib 99%
Inquiry

SHOBHA LIFE SCIENCES PRIVATE LIMITED

1Y
Phone:+919121212469
Whatsapp: +91 9121212469
product: Etoricoxib 202409-33-4 99%
Inquiry

KARUNESH REMEDIES

1Y
Phone:+919998776849
Whatsapp: +91 9998776849
product: 202409-33-4 Etoricoxib IP/BP/EP/USP Complies as per Monograph
Inquiry

PUNJAB CHEMICALS AND CROP PROTECTION LTD

1Y
Phone:+917508355205
Whatsapp: +91 7508355205
product: Etoricoxib 99%
Inquiry

Gennex Laboratories Limited

1Y
Phone:+919346516012
Whatsapp: +91 9346516012
product: ETORICOXIB 99%
Inquiry

Mana Pharma

1Y
Phone:+91-9989566060
Whatsapp: +91 9989566060
product: Etoricoxib 98%
Inquiry

Metrochem API Private Limited

1Y
Phone:+91-4069069999
product: Etoricoxib 98%
Inquiry

Otto Chemie Pvt Ltd

1Y
Phone:+91-2266382599
product: Etoricoxib 98%
Inquiry

Alembic Pharmaceuticals Limited

1Y
Phone:+912652280550
product: Etoricoxib 98%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.